Europe Fibrotic Diseases Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

Europe fibrotic diseases treatment market is projected to register a substantial CAGR of 6.0%in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe fibrotic diseases treatment market are:

Technological advancement in the treatment of fibrosis diseases

Increase in the number of people smoking cigarettes

Market Players:

Some of the key market players in the Europe fibrotic diseases treatment market are listed below:

Boehringer Ingelheim International GmbH

AbbVie Inc.

Redx Pharma Plc

Bristol-Myers Squibb Company

Gilead Sciences, Inc.

KITHER BIOTECH S.R.L.

Verona Pharma plc

Intercept Pharmaceuticals, Inc.

Pharmaxis Ltd.

Teva Pharmaceutical Industries Ltd.

Sandoz International GmbH

1 INTRODUCTION 33

1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE EUROPE FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35

2 MARKET SEGMENTATION 37

2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48

3 EXECUTIVE SUMMARY 49

4 PREMIUM INSIGHTS 51

4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53

5 EPIDEMIOLOGY 54

5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55

6 INDUSTRY INSIGHTS 56

6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58

7 MERGERS AND ACQUISITIONS 60

7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60

8 PIPELINE ANALYSIS 61

8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61

9 EUROPE FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62

9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63

10 MARKET OVERVIEW 64

10.1 DRIVERS 66
- 10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
- 10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
- 10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
- 10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
- 10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
- 10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
- 10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
- 10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
- 10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69

11 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70

11.1 OVERVIEW 71
11.2 MEDICATION 73
- 11.2.1 INTEDANIB (OFEV) 74
- 11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76

12 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77

12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84

13 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85

13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91

14 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92

14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97

15 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98

15.1 EUROPE 99
- 15.1.1 GERMANY 106
- 15.1.2 FRANCE 108
- 15.1.3 U.K. 110
- 15.1.4 ITALY 112
- 15.1.5 SPAIN 114
- 15.1.6 RUSSIA 116
- 15.1.7 TURKEY 118
- 15.1.8 NETHERLANDS 120
- 15.1.9 SWITZERLAND 122
- 15.1.10 HUNGARY 124
- 15.1.11 LITHUANIA 126
- 15.1.12 AUSTRIA 128
- 15.1.13 IRELAND 130
- 15.1.14 NORWAY 132
- 15.1.15 POLAND 134
- 15.1.16 REST OF EUROPE 136

16 EUROPE FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 137

16.1 COMPANY SHARE ANALYSIS: EUROPE 137

17 SWOT ANALYSIS 138

18 COMPANY PROFILE 139

18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 139
- 18.1.1 COMPANY SNAPSHOT 139
- 18.1.2 REVENUE ANALYSIS 139
- 18.1.3 COMPANY SHARE ANALYSIS 140
- 18.1.4 PRODUCT PORTFOLIO 140
- 18.1.5 RECENT DEVELOPMENTS 140
18.2 GENENTECH, INC. 141
- 18.2.1 COMPANY SNAPSHOT 141
- 18.2.2 COMPANY SHARE ANALYSIS 141
- 18.2.3 PRODUCT PORTFOLIO 142
- 18.2.4 RECENT DEVELOPMENTS 142
18.3 SANDOZ INTERNATIONAL GMBH 143
- 18.3.1 COMPANY SNAPSHOT 143
- 18.3.2 COMPANY SHARE ANALYSIS 143
- 18.3.3 PRODUCT PORTFOLIO 144
- 18.3.4 RECENT DEVELOPMENTS 144
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 145
- 18.4.1 COMPANY SNAPSHOT 145
- 18.4.2 REVENUE ANALYSIS 145
- 18.4.3 COMPANY SHARE ANALYSIS 146
- 18.4.4 PRODUCT PORTFOLIO 146
- 18.4.5 RECENT DEVELOPMENTS 146
18.5 ACCORD HEALTHCARE U.S. 147
- 18.5.1 COMPANY SNAPSHOT 147
- 18.5.2 COMPANY SHARE ANALYSIS 147
- 18.5.3 PRODUCT PORTFOLIO 148
- 18.5.4 RECENT DEVELOPMENTS 148
18.6 ABBVIE INC. 149
- 18.6.1 COMPANY SNAPSHOT 149
- 18.6.2 REVENUE ANALYSIS 149
- 18.6.3 PRODUCT PORTFOLIO 150
- 18.6.4 RECENT DEVELOPMENTS 150
18.7 ALPINE IMMUNE SCIENCES 151
- 18.7.1 COMPANY SNAPSHOT 151
- 18.7.2 REVENUE ANALYSIS 151
- 18.7.3 PRODUCT PORTFOLIO 152
- 18.7.4 RECENT DEVELOPMENTS 152
18.8 BELLBROOK LABS 153
- 18.8.1 COMPANY SNAPSHOT 153
- 18.8.2 PRODUCT PORTFOLIO 153
- 18.8.3 RECENT DEVELOPMENTS 153
18.9 BIOMX 154
- 18.9.1 COMPANY SNAPSHOT 154
- 18.9.2 REVENUE ANALYSIS 154
- 18.9.3 PRODUCT PORTFOLIO 155
- 18.9.4 RECENT DEVELOPMENTS 155
18.10 BRISTOL-MYERS SQUIBB COMPANY 156
- 18.10.1 COMPANY SNAPSHOT 156
- 18.10.2 REVENUE ANALYSIS 156
- 18.10.3 PRODUCT PORTFOLIO 157
- 18.10.4 RECENT DEVELOPMENTS 157
18.11 CAMBER PHARMACEUTICALS, INC. 158
- 18.11.1 COMPANY SNAPSHOT 158
- 18.11.2 PRODUCT PORTFOLIO 158
- 18.11.3 RECENT DEVELOPMENTS 158
18.12 ENVEDA 159
- 18.12.1 COMPANY SNAPSHOT 159
- 18.12.2 PRODUCT PORTFOLIO 159
- 18.12.3 RECENT DEVELOPMENTS 159
18.13 GILEAD SCIENCES, INC. 160
- 18.13.1 COMPANY SNAPSHOT 160
- 18.13.2 REVENUE ANALYSIS 160
- 18.13.3 PRODUCT PORTFOLIO 161
- 18.13.4 RECENT DEVELOPMENTS 161
18.14 INTERCEPT PHARMACEUTICALS, INC. 162
- 18.14.1 COMPANY SNAPSHOT 162
- 18.14.2 REVENUE ANALYSIS 162
- 18.14.3 PRODUCT PORTFOLIO 163
- 18.14.4 RECENT DEVELOPMENTS 163
18.15 KITHER BIOTECH S.R.L. 164
- 18.15.1 COMPANY SNAPSHOT 164
- 18.15.2 PRODUCT PORTFOLIO 164
- 18.15.3 RECENT DEVELOPMENTS 164
18.16 PHARMAXIS LTD 165
- 18.16.1 COMPANY SNAPSHOT 165
- 18.16.2 REVENUE ANALYSIS 165
- 18.16.3 PRODUCT PORTFOLIO 166
- 18.16.4 RECENT DEVELOPMENTS 166
18.17 REDX PHARMA PLC. 167
- 18.17.1 COMPANY SNAPSHOT 167
- 18.17.2 REVENUE ANALYSIS 167
- 18.17.3 PRODUCT PORTFOLIO 168
- 18.17.4 RECENT DEVELOPMENTS 168
18.18 VERONA PHARMA PLC 169
- 18.18.1 COMPANY SNAPSHOT 169
- 18.18.2 REVENUE ANALYSIS 169
- 18.18.3 PRODUCT PORTFOLIO 170
- 18.18.4 RECENT DEVELOPMENTS 170

19 QUESTIONNAIRE 171

20 RELATED REPORTS 174

LIST OF TABLES

TABLE 1 EUROPE FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 47
TABLE 2 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 59
TABLE 3 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 60
TABLE 4 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 60
TABLE 5 EUROPE ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 6 EUROPE OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 62
TABLE 7 EUROPE OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 62
TABLE 8 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 66
TABLE 9 EUROPE IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 10 EUROPE HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 11 EUROPE RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 12 EUROPE CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 13 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
TABLE 14 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 74
TABLE 15 EUROPE HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 16 EUROPE SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 17 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 18 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 19 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 81
TABLE 20 EUROPE HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 21 EUROPE RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 22 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 23 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 89
TABLE 24 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 89
TABLE 25 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 89
TABLE 26 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 90
TABLE 27 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 90
TABLE 28 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 90
TABLE 29 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 90
TABLE 30 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 91
TABLE 31 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 92
TABLE 32 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 92
TABLE 33 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 92
TABLE 34 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 92
TABLE 35 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 93
TABLE 36 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 93
TABLE 37 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 93
TABLE 38 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 94
TABLE 39 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 94
TABLE 40 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 94
TABLE 41 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 94
TABLE 42 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 95
TABLE 43 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 95
TABLE 44 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
TABLE 45 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 96
TABLE 46 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 96
TABLE 47 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 96
TABLE 48 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 96
TABLE 49 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 97
TABLE 50 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 97
TABLE 51 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 97
TABLE 52 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 98
TABLE 53 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 98
TABLE 54 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 98
TABLE 55 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 98
TABLE 56 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 99
TABLE 57 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 99
TABLE 58 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 99
TABLE 59 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 100
TABLE 60 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 100
TABLE 61 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 100
TABLE 62 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 100
TABLE 63 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 101
TABLE 64 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 101
TABLE 65 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 101
TABLE 66 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 102
TABLE 67 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 102
TABLE 68 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 102
TABLE 69 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 102
TABLE 70 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 103
TABLE 71 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 103
TABLE 72 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 103
TABLE 73 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 104
TABLE 74 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 104
TABLE 75 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 104
TABLE 76 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 104
TABLE 77 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 105
TABLE 78 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 105
TABLE 79 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 105
TABLE 80 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 106
TABLE 81 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 106
TABLE 82 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 106
TABLE 83 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 106
TABLE 84 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 107
TABLE 85 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 107
TABLE 86 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 107
TABLE 87 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 108
TABLE 88 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 108
TABLE 89 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 108
TABLE 90 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 108
TABLE 91 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 109
TABLE 92 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 109
TABLE 93 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 109
TABLE 94 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 110
TABLE 95 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 110
TABLE 96 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 110
TABLE 97 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 110
TABLE 98 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 111
TABLE 99 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 111
TABLE 100 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 111
TABLE 101 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 112
TABLE 102 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 112
TABLE 103 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 112
TABLE 104 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 112
TABLE 105 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 113
TABLE 106 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 113
TABLE 107 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 113
TABLE 108 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 114
TABLE 109 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 114
TABLE 110 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 114
TABLE 111 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 114
TABLE 112 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 115
TABLE 113 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 115
TABLE 114 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 115
TABLE 115 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 116
TABLE 116 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 116
TABLE 117 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 116
TABLE 118 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 116
TABLE 119 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 117
TABLE 120 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 117
TABLE 121 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
TABLE 122 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 118
TABLE 123 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 118
TABLE 124 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 118
TABLE 125 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 118
TABLE 126 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 119
TABLE 127 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 119
TABLE 128 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 119
TABLE 129 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 120
TABLE 130 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 120
TABLE 131 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 120
TABLE 132 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 120
TABLE 133 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 121
TABLE 134 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 121
TABLE 135 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 121
TABLE 136 REST OF EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 122

LIST OF FIGURES

FIGURE 1 EUROPE FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 22
FIGURE 2 EUROPE FIBROTIC DISEASES TREATMENT MARKET: DATA TRIANGULATION 25
FIGURE 3 EUROPE FIBROTIC DISEASES TREATMENT MARKET: DROC ANALYSIS 26
FIGURE 4 EUROPE FIBROTIC DISEASES TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 27
FIGURE 5 EUROPE FIBROTIC DISEASES TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 27
FIGURE 6 EUROPE FIBROTIC DISEASES TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 29
FIGURE 7 EUROPE FIBROTIC DISEASES TREATMENT MARKET: DBMR MARKET POSITION GRID 30
FIGURE 8 EUROPE FIBROTIC DISEASES TREATMENT MARKET: MARKET END USER COVERAGE GRID 31
FIGURE 9 EUROPE FIBROTIC DISEASES TREATMENT MARKET : VENDOR SHARE ANALYSIS 32
FIGURE 10 EUROPE FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 35
FIGURE 11 RISING PREVALENCE OF FIBROTIC DISEASES IS EXPECTED TO DRIVE THE EUROPE FIBROTIC DISEASES TREATMENT MARKET GROWTH IN THE FORECAST PERIOD 36
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE FIBROTIC DISEASES TREATMENT MARKET IN 2023 & 2030 36
FIGURE 13 PATIENT FLOW DIAGRAM 44
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE FIBROTIC DISEASES TREATMENT MARKET 50
FIGURE 15 EUROPE FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2022 56
FIGURE 16 EUROPE FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2023-2030 (USD THOUSAND) 57
FIGURE 17 EUROPE FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT CAGR (2023-2030) 57
FIGURE 18 EUROPE FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT LIFELINE CURVE 58
FIGURE 19 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2022 63
FIGURE 20 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND) 64
FIGURE 21 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, CAGR (2023-2030) 64
FIGURE 22 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE 65
FIGURE 23 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2022 71
FIGURE 24 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 72
FIGURE 25 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY END USER, CAGR (2023-2030) 72
FIGURE 26 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY END USER, LIFELINE CURVE 73
FIGURE 27 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 78
FIGURE 28 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 79
FIGURE 29 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 79
FIGURE 30 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 80
FIGURE 31 EUROPE FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 85
FIGURE 32 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 86
FIGURE 33 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 86
FIGURE 34 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 87
FIGURE 35 EUROPE FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 87
FIGURE 36 EUROPE FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%) 122